MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F82

Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community

Identifieur interne : 000F82 ( PascalFrancis/Corpus ); précédent : 000F81; suivant : 000F83

Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community

Auteurs : Prachi Mehta ; George D. Mellick ; Dominic B. Rowe ; Glenda M. Halliday ; Michael M. Jones ; Neil Manwaring ; Himesha Vandebona ; Peter A. Silbum ; JIE JIN WANG ; Paul Mitchell ; Carolyn M. Sue

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0104582

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, DNA mitochondrial, Prévention, Prévalence.

English descriptors

KwdEn :
- Mitochondrial DNA, Nervous system diseases, Parkinson disease, Prevalence, Prevention.

Abstract

MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community`
A11	`01`	`1`		`@1 MEHTA (Prachi)`
A11	`02`	`1`		`@1 MELLICK (George D.)`
A11	`03`	`1`		`@1 ROWE (Dominic B.)`
A11	`04`	`1`		`@1 HALLIDAY (Glenda M.)`
A11	`05`	`1`		`@1 JONES (Michael M.)`
A11	`06`	`1`		`@1 MANWARING (Neil)`
A11	`07`	`1`		`@1 VANDEBONA (Himesha)`
A11	`08`	`1`		`@1 SILBUM (Peter A.)`
A11	`09`	`1`		`@1 JIE JIN WANG`
A11	`10`	`1`		`@1 MITCHELL (Paul)`
A11	`11`	`1`		`@1 SUE (Carolyn M.)`
A14	`01`			`@1 Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney @2 Sydney @3 AUS @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 11 aut.`
A14	`02`			`@1 Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland @2 Queensland @3 AUS @Z 2 aut. @Z 8 aut.`
A14	`03`			`@1 Prince of Wales Medical Research Institute and University of New South Wales @2 Sydney @3 AUS @Z 4 aut.`
A14	`04`			`@1 Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney @2 Sydney @3 AUS @Z 9 aut. @Z 10 aut.`
A14	`05`			`@1 Centre for Eye Research Australia, University of Melbourne @2 Melbourne @3 AUS @Z 9 aut.`
A20				`@1 290-292`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000184195990210`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 8 ref.`
A47	`01`	`1`		`@0 09-0104582`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 DNA mitochondrial @5 09`
C03	`03`	`X`	`ENG`	`@0 Mitochondrial DNA @5 09`
C03	`03`	`X`	`SPA`	`@0 DNA mitocondrial @5 09`
C03	`04`	`X`	`FRE`	`@0 Prévention @5 10`
C03	`04`	`X`	`ENG`	`@0 Prevention @5 10`
C03	`04`	`X`	`SPA`	`@0 Prevención @5 10`
C03	`05`	`X`	`FRE`	`@0 Prévalence @5 11`
C03	`05`	`X`	`ENG`	`@0 Prevalence @5 11`
C03	`05`	`X`	`SPA`	`@0 Prevalencia @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 075`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0104582 INIST
ET :	Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community
AU :	MEHTA (Prachi); MELLICK (George D.); ROWE (Dominic B.); HALLIDAY (Glenda M.); JONES (Michael M.); MANWARING (Neil); VANDEBONA (Himesha); SILBUM (Peter A.); JIE JIN WANG; MITCHELL (Paul); SUE (Carolyn M.)
AF :	Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney/Sydney/Australie (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 11 aut.); Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland/Queensland/Australie (2 aut., 8 aut.); Prince of Wales Medical Research Institute and University of New South Wales/Sydney/Australie (4 aut.); Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney/Sydney/Australie (9 aut., 10 aut.); Centre for Eye Research Australia, University of Melbourne/Melbourne/Australie (9 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 2; Pp. 290-292; Bibl. 8 ref.
LA :	Anglais
EA :	MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; DNA mitochondrial; Prévention; Prévalence
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Mitochondrial DNA; Prevention; Prevalence
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; DNA mitocondrial; Prevención; Prevalencia
LO :	INIST-20953.354000184195990210
ID :	09-0104582

Links to Exploration step

Pascal:09-0104582

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community</title>
<author><name sortKey="Mehta, Prachi" sort="Mehta, Prachi" uniqKey="Mehta P" first="Prachi" last="Mehta">Prachi Mehta</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mellick, George D" sort="Mellick, George D" uniqKey="Mellick G" first="George D." last="Mellick">George D. Mellick</name>
<affiliation><inist:fA14 i1="02"><s1>Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rowe, Dominic B" sort="Rowe, Dominic B" uniqKey="Rowe D" first="Dominic B." last="Rowe">Dominic B. Rowe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name>
<affiliation><inist:fA14 i1="03"><s1>Prince of Wales Medical Research Institute and University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Michael M" sort="Jones, Michael M" uniqKey="Jones M" first="Michael M." last="Jones">Michael M. Jones</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manwaring, Neil" sort="Manwaring, Neil" uniqKey="Manwaring N" first="Neil" last="Manwaring">Neil Manwaring</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vandebona, Himesha" sort="Vandebona, Himesha" uniqKey="Vandebona H" first="Himesha" last="Vandebona">Himesha Vandebona</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Silbum, Peter A" sort="Silbum, Peter A" uniqKey="Silbum P" first="Peter A." last="Silbum">Peter A. Silbum</name>
<affiliation><inist:fA14 i1="02"><s1>Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jie Jin Wang" sort="Jie Jin Wang" uniqKey="Jie Jin Wang" last="Jie Jin Wang">JIE JIN WANG</name>
<affiliation><inist:fA14 i1="04"><s1>Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Centre for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name>
<affiliation><inist:fA14 i1="04"><s1>Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sue, Carolyn M" sort="Sue, Carolyn M" uniqKey="Sue C" first="Carolyn M." last="Sue">Carolyn M. Sue</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0104582</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0104582 INIST</idno>
<idno type="RBID">Pascal:09-0104582</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community</title>
<author><name sortKey="Mehta, Prachi" sort="Mehta, Prachi" uniqKey="Mehta P" first="Prachi" last="Mehta">Prachi Mehta</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mellick, George D" sort="Mellick, George D" uniqKey="Mellick G" first="George D." last="Mellick">George D. Mellick</name>
<affiliation><inist:fA14 i1="02"><s1>Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rowe, Dominic B" sort="Rowe, Dominic B" uniqKey="Rowe D" first="Dominic B." last="Rowe">Dominic B. Rowe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name>
<affiliation><inist:fA14 i1="03"><s1>Prince of Wales Medical Research Institute and University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jones, Michael M" sort="Jones, Michael M" uniqKey="Jones M" first="Michael M." last="Jones">Michael M. Jones</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manwaring, Neil" sort="Manwaring, Neil" uniqKey="Manwaring N" first="Neil" last="Manwaring">Neil Manwaring</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vandebona, Himesha" sort="Vandebona, Himesha" uniqKey="Vandebona H" first="Himesha" last="Vandebona">Himesha Vandebona</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Silbum, Peter A" sort="Silbum, Peter A" uniqKey="Silbum P" first="Peter A." last="Silbum">Peter A. Silbum</name>
<affiliation><inist:fA14 i1="02"><s1>Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jie Jin Wang" sort="Jie Jin Wang" uniqKey="Jie Jin Wang" last="Jie Jin Wang">JIE JIN WANG</name>
<affiliation><inist:fA14 i1="04"><s1>Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Centre for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name>
<affiliation><inist:fA14 i1="04"><s1>Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sue, Carolyn M" sort="Sue, Carolyn M" uniqKey="Sue C" first="Carolyn M." last="Sue">Carolyn M. Sue</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Mitochondrial DNA</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Prevention</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>DNA mitochondrial</term>
<term>Prévention</term>
<term>Prévalence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MEHTA (Prachi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MELLICK (George D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROWE (Dominic B.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HALLIDAY (Glenda M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JONES (Michael M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MANWARING (Neil)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>VANDEBONA (Himesha)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SILBUM (Peter A.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JIE JIN WANG</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MITCHELL (Paul)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SUE (Carolyn M.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Prince of Wales Medical Research Institute and University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Centre for Eye Research Australia, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>290-292</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184195990210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>8 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0104582</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>DNA mitochondrial</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mitochondrial DNA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>DNA mitocondrial</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévention</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevention</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevención</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>075</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0104582 INIST</NO>
<ET>Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community</ET>
<AU>MEHTA (Prachi); MELLICK (George D.); ROWE (Dominic B.); HALLIDAY (Glenda M.); JONES (Michael M.); MANWARING (Neil); VANDEBONA (Himesha); SILBUM (Peter A.); JIE JIN WANG; MITCHELL (Paul); SUE (Carolyn M.)</AU>
<AF>Department of Neurology and Neurogenetics, Kolling Institute, Royal North Shore Hospital and University of Sydney/Sydney/Australie (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 11 aut.); Eskitis Institute for Cell and Molecular Therapies, Griffith University and School of Medicine, University of Queensland/Queensland/Australie (2 aut., 8 aut.); Prince of Wales Medical Research Institute and University of New South Wales/Sydney/Australie (4 aut.); Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney/Sydney/Australie (9 aut., 10 aut.); Centre for Eye Research Australia, University of Melbourne/Melbourne/Australie (9 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 2; Pp. 290-292; Bibl. 8 ref.</SO>
<LA>Anglais</LA>
<EA>MtDNA haplogroups J and K have been associated with a decreased risk of developing Parkinson's disease (PD). To confirm this finding, we compared the distribution of mtDNA haplogroups J and K in a large sample of Australian patients with PD (n - 890) to population-based controls (n = 3,491). We assigned subjects to haplogroups J or K using standard PCR/RFLP techniques. Of the 890 subjects with PD, 10.6% were haplogroup J (95% CI 8.6-12.8, n = 94) and 7.1% were haplogroup K (95% CI 5.5-8.9, n = 63). In our controls, 10.2% belonged to haplogroup J (95% CI 9.2-11.2, n = 356), and 7.8% were in haplogroup K (95% CI 6.9-8.7, n = 272). There was no significant difference in the prevalence of mtDNA haplogroup J or K in PD patients compared to population-based controls. Our findings indicate that mtDNA haplogroups J and K are not associated with a lower risk of PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; DNA mitochondrial; Prévention; Prévalence</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Mitochondrial DNA; Prevention; Prevalence</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; DNA mitocondrial; Prevención; Prevalencia</SD>
<LO>INIST-20953.354000184195990210</LO>
<ID>09-0104582</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F82 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F82 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0104582
   |texte=   Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community

Mitochondrial DNA Haplogroups J and K are not Protective for Parkinson's Disease in the Australian Community

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri